Patients with cervical cancer who have elevated VEGF levels are treated with bevacizumab, a monoclonal antibody that targets VEGF-A, which prevents signal transmission through VEGF receptors 1 and 2 and tends to suppress its activity [8,16]. Here, VEGFA is linked to cervical carcinoma.